Peripheral Arterial Disease

• 

  Subject Areas on Research

  • ACCF/AHA/ACR/SCAI/SIR/SVM/SVN/SVS 2010 performance measures for adults with peripheral artery disease. A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures, the American College of Radiology, the Society for Cardiac Angiography and Interventions, the Society for Interventional Radiology, the Society for Vascular Medicine, the Society for Vascular Nursing, and the Society for Vascular Surgery (Writing Committee to Develop Clinical Performance Measures for Peripheral Artery Disease). 
  • ACCF/AHA/ACR/SCAI/SIR/SVM/SVN/SVS 2010 performance measures for adults with peripheral artery disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures, the American College of Radiology, the Society for Cardiac Angiography and Interventions, the Society for Interventional Radiology, the Society for Vascular Medicine, the Society for Vascular Nursing, and the Society for Vascular Surgery (Writing Committee to Develop Clinical Performance Measures for Peripheral Artery Disease). 
  • ADAM12 Modifies Severity of Peripheral Arterial Disease; Evidence From Preclinical and Human Studies 
  • ADAM12: a genetic modifier of preclinical peripheral arterial disease. 
  • Alteration in angiogenic and anti-angiogenic forms of vascular endothelial growth factor-A in skeletal muscle of patients with intermittent claudication following exercise training. 
  • An endovascular model of ischemic myopathy from peripheral arterial disease. 
  • An evidence-based score to detect prevalent peripheral artery disease (PAD). 
  • Anatomic runoff score predicts cardiovascular outcomes in patients with lower extremity peripheral artery disease undergoing revascularization. 
  • Angiogenesis in skeletal muscle precede improvements in peak oxygen uptake in peripheral artery disease patients. 
  • Ankle-brachial index and cardiovascular risk prediction: an analysis of 11,594 individuals with 10-year follow-up. 
  • Ankle-brachial index as a predictor of coronary disease events in elderly patients submitted to coronary angiography. 
  • Antithrombotic Therapy After Peripheral Vascular Intervention. 
  • Balancing the risks and benefits of long-term antiplatelet therapies for cardiovascular disease: clinical, research, and regulatory implications. 
  • Cardiovascular Events in Acute Coronary Syndrome Patients With Peripheral Arterial Disease Treated With Ticagrelor Compared to Clopidogrel: Data From the PLATO Trial 
  • Cardiovascular disease in chronic kidney disease. A clinical update from Kidney Disease: Improving Global Outcomes (KDIGO). 
  • Clinical trials in peripheral vascular disease: pipeline and trial designs: an evaluation of the ClinicalTrials.gov database. 
  • Co-existence of vascular disease in different arterial beds: Peripheral artery disease and carotid artery stenosis--Data from Life Line Screening(®). 
  • Comparative effectiveness of endovascular and surgical revascularization for patients with peripheral artery disease and critical limb ischemia: systematic review of revascularization in critical limb ischemia. 
  • Comparative effectiveness review of antiplatelet agents in peripheral artery disease. 
  • Contemporary Treatment and Outcomes of Peripheral Vascular Interventions for Symptomatic Lower Extremity Peripheral Arterial Disease: Insights From the National VA Clinical Assessment, Reporting and Tracking (VA-CART) Program Peripheral Registry 
  • Design and rationale for the Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) trial. 
  • Dietary nitrate supplementation enhances exercise performance in peripheral arterial disease. 
  • Distribution of ankle--brachial index and the risk factors of peripheral artery disease in a multi-ethnic Asian population. 
  • Effect of peripheral arterial disease on functional and clinical outcomes in patients with heart failure (from HF-ACTION). 
  • Efficacy and Safety of Apixaban Compared With Warfarin in Patients With Atrial Fibrillation and Peripheral Artery Disease: Insights From the ARISTOTLE Trial. 
  • Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF. 
  • Endovascular procedures for aorto-iliac occlusive disease are associated with superior short-term clinical and economic outcomes compared with open surgery in the inpatient population. 
  • Evaluation and treatment of patients with lower extremity peripheral artery disease: consensus definitions from Peripheral Academic Research Consortium (PARC). 
  • Fibrosis-related biomarkers and large and small vessel disease: the Cardiovascular Health Study. 
  • Genetic Variants in the Bone Morphogenic Protein (BMP) Family of Genes Interact with Mobile Source Air Pollution to Increase Risk of Peripheral Arterial Disease 
  • Genetic Variants in the Bone Morphogenic Protein Gene Family Modify the Association between Residential Exposure to Traffic and Peripheral Arterial Disease. 
  • Laser in infrapopliteal and popliteal stenosis 2 study (LIPS2): Long-term outcomes of laser-assisted balloon angioplasty versus balloon angioplasty for below knee peripheral arterial disease. 
  • Learning to walk before we run: the mechanics of medical intervention for peripheral arterial disease. 
  • Limb ischemia: cardiovascular diagnosis and management from head to toe. 
  • Longitudinal changes in high-density lipoprotein cholesterol and cardiovascular events in older adults. 
  • Lower extremity amputation in peripheral artery disease: improving patient outcomes. 
  • Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA Guideline Recommendations): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 
  • Management of patients with peripheral artery disease (compilation of 2005 and 2011 ACCF/AHA guideline recommendations): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. 
  • Missed opportunities: despite improvement in use of cardioprotective medications among patients with lower-extremity peripheral artery disease, underuse remains. 
  • Novel CenterCross and MultiCross devices for the treatment of infrainguinal chronic total occlusions: initial single-centre experience. 
  • Outcome of lower extremity revascularization for peripheral artery occlusive disease: is there a difference between men and women? 
  • Outcomes of surgical revascularization for lower extremity arterial thromboembolism in patients with advanced malignancy. 
  • Peripheral Artery Disease Therapies May Perform Differently in Practice Than in Randomized Trials: The Need for Learning Health Systems. 
  • Peripheral Artery Disease is Associated with Worse Functional and Clinical Outcomes in Heart Failure Patients: HF-ACTION substudy 
  • Peripheral arterial testing before lower extremity amputation among Medicare beneficiaries, 2000 to 2010. 
  • Peripheral artery disease is a coronary heart disease risk equivalent among both men and women: results from a nationwide study. 
  • Polyvascular disease and long-term cardiovascular outcomes in older patients with non-ST-segment-elevation myocardial infarction. 
  • Predictors of contemporary coronary artery bypass grafting outcomes. 
  • Relation of Baseline Renal Dysfunction With Outcomes in Patients Undergoing Popliteal and Infrapopliteal Percutaneous Peripheral Arterial Interventions. 
  • Relationship between leg muscle capillary density and peak hyperemic blood flow with endurance capacity in peripheral artery disease. 
  • Relationship of systemic endothelial function and peripheral arterial stiffness with diabetic retinopathy. 
  • Reply: Era of Change in Sites of Service for Peripheral Vascular Intervention Requires New Ways to Look at Costs. 
  • Response to Letter to the Editor regarding "Anatomic runoff score predicts cardiovascular outcomes in patients with lower extremity peripheral artery disease undergoing revascularization". 
  • Safety and efficacy metrics for primary nitinol stenting in femoropopliteal occlusive disease: a meta-analysis and critical examination of current methodologies. 
  • Spliced arm vein grafts are a durable conduit for lower extremity bypass. 
  • Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. 
  • Statin therapy--Part II: Clinical considerations for cardiovascular disease. 
  • Supervised vs. Unsupervised Exercise for the treatment of Intermittent Claudication: a Network Meta-analysis 
  • Temporal trends and geographic variation of lower-extremity amputation in patients with peripheral artery disease: results from U.S. Medicare 2000-2008. 
  • The Contemporary Safety and Effectiveness of Lower Extremity Bypass Surgery and Peripheral Endovascular Interventions in the Treatment of Symptomatic Peripheral Arterial Disease. 
  • The LargPAD Trial: Phase IIA evaluation of l-arginine infusion in patients with peripheral arterial disease. 
  • The eMERGE Network: a consortium of biorepositories linked to electronic medical records data for conducting genomic studies. 
  • Ticagrelor Compared With Clopidogrel in Patients With Prior Lower Extremity Revascularization for Peripheral Artery Disease. 
  • Ticagrelor versus Clopidogrel in Peripheral Artery Disease. 
  • Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease. 
  • Trends in settings for peripheral vascular intervention and the effect of changes in the outpatient prospective payment system. 
  • Use of Cardioprotective Medications Remain Underused in Patients with Peripheral Arterial Disease 
  • Use of endovascular therapy for peripheral arterial lesions: an analysis of the National Trauma Data Bank from 2007 to 2009. 
  • VEGF and VEGF-R1 Levels in Skeletal Muscle of PAD Patients: A Report From the AMNESTI (Angiogenesis and Mechanisms of Exercise Training in PAD) Clinical Trial 
  • Vorapaxar and diplopia: Possible off-target PAR-receptor mismodulation. 
  • Vorapaxar in Non-ST-Segment Elevation Acute Coronary Syndrome Patients With Peripheral Artery Disease: Results From TRACER 
  • Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER). 
• 

  Keywords of People

  • Jones, William Schuyler, Associate Professor of Medicine, Medicine, Cardiology